Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
  • giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
  • Ibrance® (palbociclib): High Risk Early Breast Cancer
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of July 28, 2020

  • Discovery Projects
  • Phase 1
    25
  • Phase 2
    38
  • Phase 3
    23
  • Registration
    4
  • Total90
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (infants) (FAST TRACK)
Project advanced
Phase 3 Product Enhancement Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY Meningococcal Infections (adolescent and young adults)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-07302048 (BNT162)
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
Go to clinical trial
COVID-19 Infection (in partnership with BioNTech) (FAST TRACK) (Pivotal Phase 2/3 global study)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) Phase 2 New Molecular Entity Vaccine
PF-07307405
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Lyme disease
Project advanced
Phase 2 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (E.U.) Registration Biosimilar Biosimilar
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Metastatic Castration Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) (E.U.)
Project advanced
Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/cytarabine and daunorubicin in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic